Blog
Archives: FAQs
-
Can a protest be submitted anonymously?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How can a third party anonymously request ex parte reexamination?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How is the regulatory review period for an animal drug determined?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How should examiners analyze claims for ‘significantly more’ in Step 2B?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How should examiners analyze claims for integration into a practical application?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is the difference between the ‘same field of endeavor’ and ‘reasonably pertinent’ tests for analogous art?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is considered analogous art for obviousness rejections?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is the significance of “analogous art” in determining enablement for chemical compounds?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
Thirty minutes. Chief IP Officer on retainer — and the capital option behind it.
If what you need is something else, we’ll tell you on the same call.